Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

India's Best Lithium Stocks
Discover the Best Possible Way to
Ride Astonishing Growth in EVs

Revealing Full Details TODAY @ 5pm

mailtimers.com


**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
**By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.


AD

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis
Sat, 31 Mar

ASTRAZENECA PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

ASTRAZENECA PHARMA Income Statement Analysis

  • Operating income during the year rose 5.8% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 25.3% YoY during the fiscal. Operating profit margins witnessed a fall and down at 8.1% in FY18 as against 6.9% in FY17.
  • Depreciation charges decreased by 6.9% increased by 0.0% YoY, respectively.
  • Other income declined by 14.9% YoY.
  • Net profit for the year grew by 29.2% YoY.
  • Net profit margins during the year grew from 3.7% in FY17 to 4.5% in FY18.

ASTRAZENECA PHARMA Income Statement 2017-18

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Net Sales Rs m 5,388 5,700 5.8%
Other income Rs m 144 123 -14.9%
Total Revenues Rs m 5,532 5,823 5.3%
Gross profit Rs m 369 463 25.3%
Depreciation Rs m 158 147 -6.9%
Interest Rs m 0 0 0.0%
Profit before tax Rs m 355 438 23.4%
Tax Rs m 155 179 15.8%
Profit after tax Rs m 201 259 29.2%
Gross profit margin % 6.9 8.1
Effective tax rate % 43.5 40.8
Net profit margin % 3.7 4.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Today at 5pm: India's Best Lithium Stocks

ASTRAZENECA PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 2 billion as compared to Rs 2 billion in FY17, thereby witnessing an increase of 8.2%.
  • Current assets rose 26% and stood at Rs 3 billion, while fixed assets fell 3% and stood at Rs 2 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 6 billion as against Rs 5 billion during FY17, thereby witnessing a growth of 12%.

ASTRAZENECA PHARMA Balance Sheet as on March 2018

No. of Mths Year Ending 12 Mar-17* 12 Mar-18* % Change
Networth Rs m 2,212 2,449 10.7
 
Current Liabilities Rs m 2,021 2,187 8.2
Long-term Debt Rs m 0 0 0.0
Total Liabilities Rs m 5,136 5,753 12.0
 
Current assets Rs m 2,633 3,326 26.4
Fixed Assets Rs m 2,503 2,427 -3.1
Total Assets Rs m 5,136 5,753 12.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



ASTRAZENECA PHARMA Cash Flow Statement Analysis

  • ASTRAZENECA PHARMA's cash flow from operating activities (CFO) during FY18 stood at Rs 88 million on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -94 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs 0 million, an improvement of 0% on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -6 million from the Rs 384 million net cash flows seen during FY17.

ASTRAZENECA PHARMA Cash Flow Statement 2017-18

Particulars No. of months 12 12 % Change
Year Ending Mar-17 Mar-18
Cash Flow from Operating Activities Rs m 381 88 -76.9%
Cash Flow from Investing Activities Rs m 3 -94 -
Cash Flow from Financing Activities Rs m 0 0 0.0%
Net Cash Flow Rs m 384 -6 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for ASTRAZENECA PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 10.4, an improvement from the EPS of Rs 8.0 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 926.5, stands at 88.9 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 9.5 times, while the price to sales ratio stands at 4.1 times.
  • The company's price to cash flow (P/CF) ratio stood at 66.4 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Sales per share (Unadj.) Rs 215.5 228.0
TTM Earnings per share Rs 8.0 10.4
Diluted earnings per share Rs 8.0 10.4
Price to Cash Flow x 65.5 66.4
TTM P/E ratio x 96.2 88.9
Price / Book Value ratio x 12.0 11.0
Market Cap Rs m 26,550 27,007
Dividends per share (Unadj.) Rs 0.0 0.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for ASTRAZENECA PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.5x during FY18, from 1.3x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 10.6% during FY18, from 9.1% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 17.9% during FY18, from 16.0% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 4.5% during FY18, from 3.9% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-17* 12 Mar-18*
Current ratio x 1.3 1.5
Debtors’ Days Days 29 35
Interest coverage x 0.0 0.0
Debt to equity ratio x 0.0 0.0
Return on assets % 3.9 4.5
Return on equity % 9.1 10.6
Return on capital employed % 16.0 17.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how ASTRAZENECA PHARMA has performed over the last 5 years, please visit here.

ASTRAZENECA PHARMA Share Price Performance

Over the last one year, ASTRAZENECA PHARMA share price has moved down from Rs 940.7 to Rs 926.5, registering a loss of Rs 14.2 or around 1.5%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,157.6 (down 1.1%). Over the last one year it has moved down from 15,312.4 to 13,157.6, a loss of 2,155 points (down 14.1%).

Overall, the S&P BSE SENSEX is up 12.1% over the year.

(To know more, check out historical annual results for ASTRAZENECA PHARMA and quarterly results for ASTRAZENECA PHARMA)

Annual Report FAQs

What is the current share price of ASTRAZENECA PHARMA?

ASTRAZENECA PHARMA currently trades at Rs 5,472.6 per share. You can check out the latest share price performance of ASTRAZENECA PHARMA here...

What was the revenue of ASTRAZENECA PHARMA in FY18? How does it compare to earlier years?

The revenues of ASTRAZENECA PHARMA stood at Rs 5,823 m in FY18, which was up 5.3% compared to Rs 5,532 m reported in FY17.

ASTRAZENECA PHARMA's revenue has grown from Rs 5,643 m in FY16 to Rs 5,823 m in FY18.

Over the past 3 years, the revenue of ASTRAZENECA PHARMA has grown at a CAGR of 1.6%.

What was the net profit of ASTRAZENECA PHARMA in FY18? How does it compare to earlier years?

The net profit of ASTRAZENECA PHARMA stood at Rs 259 m in FY18, which was up 29.2% compared to Rs 201 m reported in FY17.

This compares to a net profit of Rs 53 m in FY16.

Over the past 3 years, ASTRAZENECA PHARMA net profit has grown at a CAGR of 122.0%.

What does the cash flow statement of ASTRAZENECA PHARMA reveal?

The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.

This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.

The cash flow statement of ASTRAZENECA PHARMA reveals:

  • Cash flow from operations decreased in FY18 and stood at Rs 88 m as compared to Rs 381 m in FY17.
  • Cash flow from investments decreased in FY18 and stood at Rs -94 m as compared to Rs 3 m in FY17.
  • Cash flow from financial activity increased in FY18 and stood at Rs 0 m as compared to Rs 0 m in FY17.

Here's the cash flow statement of ASTRAZENECA PHARMA for the past 3 years.

(Rs m)FY16FY17FY18
From Operations57038188
From Investments-363-94
From Financial Activity-500
Net Cashflow529384-6

What does the Key Ratio analysis of ASTRAZENECA PHARMA reveal?

Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.

The ratio/financial analysis of ASTRAZENECA PHARMA reveals:

  • Operating profit margins witnessed a fall and down at 8.1% in FY18 as against 6.9% in FY17.
  • Net profit margins grew from 3.7% in FY17 to 4.5% in FY18.
  • Debt to Equity ratio for FY18 stood at 0.0 as compared to 0.0 in FY17.

Here's the ratio/financial analysis of ASTRAZENECA PHARMA for the past 3 years.

 FY16FY17FY18
Operating Profit Margin (%)2.96.98.1
Net Profit Margin (%)0.93.74.5
Debt to Equity Ratio (x)0.00.00.0

Read: Latest Annual Report Analysis of ASTRAZENECA PHARMA

 

Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA 2017-18 Annual Report Analysis". Click here!